| 161 | 4 | 33 |
| 下载次数 | 被引频次 | 阅读次数 |
目的探讨雄激素受体剪接变异体7(androgen receptor splice variant-7,AR-V7)对前列腺癌(PCA)细胞的生长作用及与PI3K/AKT信号通路的相关性。方法构建pIRES2-EGFP-AR-V7重组质粒并转染人PCA细胞(prostate cancer-3,PC-3)为AR-V7重组载体组,用pIRES2-EGFP空载质粒转染PC-3为空载对照组,正常培养的PC-3为空白对照组,应用实时荧光定量PCR(quantitative real-time PCR,qRT-PCR)及蛋白免疫印迹法(western blot,WB)验证AR-V7基因及蛋白表达水平。用CCK-8细胞计数法及流式细胞仪比较各组细胞的增殖及凋亡差异,用qRT-PCR比较组间Akt、mTOR基因表达水平,用WB比较组间Akt、p-Akt、mTOR及p-mTOR的蛋白表达水平。结果AR-V7重组载体组AR-V7基因及蛋白表达水平明显高于空载对照组和空白对照组(P<0.05)。AR-V7重组载体组细胞增殖活性明显高于空载对照组和空白对照组(P<0.01)。各组细胞凋亡率差异无统计学意义(P>0.05),各组Akt、mTOR基因及蛋白表达水平差异无统计学意义(P>0.05)。ARV7重组载体组p-Akt、p-mTOR蛋白表达水平明显低于空载对照组和空白对照组(P<0.05)。结论AR-V7对前列腺癌细胞增殖有促进作用,对Akt、mTOR基因及蛋白表达无影响,但可以抑制p-Akt及p-mTOR蛋白表达。
Abstract：Objective To investigate the effect of androgen receptor splice variant-7( AR-V7)on the proliferation of prostate cancer cells and its correlation with PI3 K/AKT signaling pathway. Methods The recombinant plasmid of pIRES2-EGFP-AR-V7 was constructed to transfect into human prostate cancer cell-3(PC-3) as the AR-V7 recombination carrier group; PC-3 transfected with pIRES2-EGFP empty plasmid as the empty load control group;normal cultured PC-3 is the blank control group. The expression levels of AR-V7 gene and protein were verified by quantitative real-time PCR(qRT-PCR)and western blot(WB). CCK-8 cell counting method and flow cytometry were used to compare the differences of cell proliferation and apoptosis in each group. The gene expression levels of Akt and mTOR were compared by qRT-PCR among the groups. The protein expression levels of Akt, p-Akt, mTOR and p-mTOR were compared by WBamong the groups. Results The Levels of AR-V7 gene and protein expression in AR-V7 recombinant carrier group were significantly higher than those of the two control groups(P<0.05). The cell proliferation activity of AR-V7 recombinant carrier group was significantly higher than those of the two control groups(P<0.01). There was no significant difference in apoptosis rate among the groups(P>0.05), and there was no significant difference in Akt、mTOR genes and proteins expression level among the groups(P>0.05). The expression level of p-Akt, p-mTOR protein in AR-V7 recombinant carrier group was significantly lower than those of the two control groups(P<0.05).Conclusion AR-V7 can promote the proliferation of prostate cancer cells, while AR-V7 has no effect on the expression of Akt, mTOR genes and proteins, but it can inhibit the expression of p-Akt and p-mTOR proteins.
[1] SIEGEL R L,MILLER K D,JERMAL A.Cancer statistics,2019[J].CA Cancer J Clin,2019,69(1):7-34.
[2]郑荣寿,等.2015年中国恶性肿瘤流行情况分析.中华肿瘤杂志,2019,41(1):19-28.
[3] GRAHAM L,SCHWEIZER M T.Targeting persistent androgen receptor signaling in castration-resistant prostate cancer[J].Med Oncol,2016,33(5):44-46
[4]周世豪,陈国俊.去势抵抗性前列腺癌的治疗进展.临床泌尿外科杂志,2017,32(3):241-244.
[5] COUTINHO I,DAY T K,TILLEY W D,et al.Androgen receptor signal-ing in castration-resistant prostate cancer:a lesson in persistence[J].Endocr Relat Cancer,2016,23(12):179-T197.
[6] LUO J, ATTARD G,BALK S P,et al.Role of androgen receptor variants in prostate cancer:report from the 2017 mission androgen receptor variants meeting[J].Eur Urol,2018,73(5):715-723.
[7]张瑶,李家合. PI3K/AKT信号通路与前列腺癌关系的研究进展[J].肿瘤学杂志,2021,27(2):153-157.
[8] WU X,HE Y,ZHANG G,et al.Royleanone diterpenoid ex-hibits potent anticancer effects in LNCaP human prostate carcinoma cells by inducing mitochondrial mediated apoptosis, cell cycle arrest, suppression of cell migration and downregulation of mTOR/PI3K/AKT signalling pathway[J].BUON,2018,23(4):1055-1060.
[9]史浩楠,王婷婷,张鹏程,等.PI3K/AKT信号通路对糖尿病大鼠血糖及骨骼肌GSK-3β表达水平的影响[J].新疆医科大学学报,2020,43(9):1159-1163
[10] CARVER B S, CHAPINSKI C, WONGVIPAT J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer[J]. Cancer Cell,2011,19(4):575-586.
[11] HADDADI N, LIN Y, TRAVIS G, et al. PTEN/PTENP1:Regulating the regulator of RTK-dependent PI3K/Akt signalling, new targets for cancer therapy[J].Mol Cancer,2018,17(1):37-39.
[12] COMFORD P. EAU-ESTRO-SIOG guidelines on prostate cancer.partⅱ:treatment of relapsing, metastatic, and castration-resistant prostate cancer[J].Eur Urol,2017,71(4):630-642.
[13] CHANDRASEKAR T,YANG JC,GAO AC,et al.Mechanisms of resistance in castration-resistant prostate cancer(CRPC)[J].Transl Androl Urol,2015,4(3):365-380.
[14] BOUDAD K, SUZMAN D L, ANAGNOSTOU V, et al. Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer[J].Oncotarget,2018,9(47):28561-28571.
[15] GUO Z,YANG X,SUN F,et al.A novel androgen receptor splice variant is up-regulated during prostate cancer pro-gression and promotes androgen depletion-resistant growth[J].Cancer Res,2009,69(6):2305-2313.
[16] BRYCE A H,ANTONARAKIS E S.Androgen receptor splice variant 7 in castration-resistant prostate cancer:Clinical considerations[J].Int J Urol,2016,23(8):646-653.
[17] DE LAERA B,VAN DAM P J,WHITINGTON T,et al.Comprehensive profiling of the androgen receptor in liquid biopsies from castration-resistant prostate cancer reveals novel intra-AR stuctural variation and splice variant expression patterns[J].Eur urol,2017,72(2):192-200.
[18] SCHER H I,GRAF R P,SCHREIBER N A,et al.Assessment of the validity of nuclear-localized androgen receptor splice variant 7in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer[J].JAMA Oncol,2018,4(9):1179-1186.
[19]赵家义,韩一平.PI3K-AKT-mTOR信号通路抑制剂与肿瘤免疫治疗[J].中国肿瘤生物治疗杂志,2017,24(12):1424-1430.
[20] SHAO G, LIU Y, MA T, et al. GCN5 inhibition prevents IL-6-induced prostate cancer metastases through PI3K/PTEN/Akt signaling by inactivating Egr-1[J].Biosci Rep,2018,38(6):12-30.
[21] SHOMING B Y, DASS M S,PEARSON H B.The PI3K-AKT-mTOR pathway and prostate cancer:at the crossroads of AR, MAPK, and WNT signaling[J]. Int J Mol Sci,2020,21(12):4507-4515.
基本信息:
中图分类号:R737.25
引用信息:
[1]艾孜麦提·阿不都热合曼,马东升,安恒庆.AR-V7对前列腺癌细胞增长及Akt/mTOR信号通路的影响[J].新疆医科大学学报,2021,44(07):765-770.
基金信息:
新疆维吾尔自治区自然科学基金（2018D01C167）
2021-01-10
2021
2021-01-31
2021-07-12
2021
1
2021-07-15
2021-07-15